Elvina Almuradova· @Dr_ElvinaA · X·· 1 天前评分70
正文 · 原文
Why does abemaciclib still work after CDK4/6i? #postMONARCH #ESMO26
• Resistance is mostly ER-driven (ESR1), so switching to fulvestrant helps
• True CDK4/6 independence (RB1 loss) is rare
• Abema ≠ palbo: CDK4-selective, some CDK2 activity, continuous dosing
PFS2 & TTC HR 0.76. Modest but real.
@OncoAlert @OncBrothers @Larvol
68 浏览 · 2 赞 · 1 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.org来源：Elvina Almuradova · x.com